GRAFORCE
15.5.2023 02:01:27 CEST | Business Wire | Press release
Graforce, Germany’s leading provider of zero carbon hydrogen plants, and Worley, a leading global engineering and project delivery business, are cooperating to scale methane electrolysis (plasmalysis) starting in Australia, Pacific, Asia and China. Plasmalysis is a game changing technology, which converts natural gas, LNG, flare gas and other hydrocarbons into hydrogen without emitting CO2 or any other greenhouse gas into the atmosphere. This allows gas consumers to switch to clean-burning hydrogen without changing their energy supplier or mode of transportation. Graforce and Worley will present plasmalysis plants at APPEA 2023 in Adelaide, Australia (15-18 May) at the Worley sponsored Hydrogen Pavilion showcasing latest innovations in the hydrogen industry and its impact on decarbonization of industries and fossil fuels.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230514005004/en/
Methane Plasmalysis plants – graphics shows a 12 MW plant - convert natural gas, LNG, flare gas and other hydrocarbons into hydrogen without emitting carbon dioxide or any other greenhouse gas into the atmosphere. This allows gas consumers to switch to clean-burning hydrogen without changing their energy supplier or way of transportation. (Graphic: Business Wire)
Australia is among the largest producers of natural gas and one of the world's leading fuel suppliers. Projects to supply Germany with LNG and green hydrogen are in progress. At the same time, the country aims to reduce its CO2 emissions by more than 40 percent by 2030. Sustainable technologies like plasmalysis are an essential requirement to meet both, economic and climate targets.
“The entire APAC region is looking for green technologies for existing energy sources to achieve climate targets. The cooperation with Worley is an important step for us to quickly scale our methane plasmalysis and to open up these markets,” said Dr. Jens Hanke, CTO of Graforce.
Worley provides large scale engineering, procurement, and construction services to the energy, resources, and chemicals industries. Worley will provide engineering and project delivery services for plasmalysis plants customers in Australia and Asia. In the modular plants, a high-frequency plasma field generated by renewable electricity splits hydrocarbons such as methane into their molecular components: hydrogen and solid carbon. Compared to water electrolysis, plasmalysis requires only one-fifth the energy to produce the same amount of hydrogen. A single 20-megawatt plant can convert about 70,000 metric tons of methane into hydrogen per year and eliminate about 200,000 metric tons of CO2 emissions.
“As we scale up towards the vast quantities of renewable energy and hydrogen required to meet our Net Zero goals, our medium-term reliance on fossil fuels and in particular, natural gas and LNG, is a given. Plasmalysis marries these two realities together and enables faster decarbonisation utilising existing infrastructure. Plasmalysis is likely to be a valuable tool in the decarbonisation toolbox and contribute to our company purpose of delivering a more sustainable world,” says Gillian Cagney, Worley ANZ Managing Director.
About
Graforce is a German hydrogen technology company. Their power-to-X plants produce carbon dioxide free or carbon dioxide negative hydrogen and synthetic feedstocks – with highest efficiency and lower infrastructure costs in the multi-megawatt range. Thus, Graforce decarbonizes fossil energies, industries and the heat, transport and building sectors. Graforce is currently in the process of expanding its financial and strategic partnerships to quickly scale its hydrogen technology worldwide.
Worley is a global company headquartered in Australia and our purpose is delivering a more sustainable world. Worley is a leading global provider of professional project and asset services in the energy, chemicals and resources sectors. As a knowledge-based service provider, we use our knowledge and capabilities to support our customers to reduce their emissions and move towards a low carbon future. Worley Limited is listed on the Australian Securities Exchange (ASX: WOR).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230514005004/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
